nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.10.2009 | Original Paper

Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy

verfasst von: Stefan Wilop, Sabine von Hobe, Martina Crysandt, Albert Esser, Rainhardt Osieka, Edgar Jost

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 10/2009

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The renin-angiotensin system plays a crucial role in maintaining vascular homeostasis. Stimulation of angiotensin II type 1 receptors (AT1R) acts proangiogenically by increasing levels of vascular endothelial growth factor (VEGF). Consequently, cell culture experiments and animal studies have shown antiproliferative effects of AT1R blockers (ARB) and angiotensin I converting enzyme inhibitors (ACEI) in several malignancies. Until now, very limited clinical data for this antiangiogenic effect exists for combinations with antineoplastic chemotherapy.

Methods

A total of 287 patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy were retrospectively analysed regarding long-term medication with ACEI and ARB as well as histological type, stage, performance status, gender, age, dose-intensity of chemotherapy and survival.

Results

Patients receiving either ACEI or ARB had a 3.1 months longer median survival than non-recipients (11.7 vs. 8.6 months, HR 0.56, P = 0.03). This survival advantage could not be attributed to other established risk-factors or dose intensity of chemotherapy.

Conclusions

Addition of ACEI or ARB to platinum-based first-line chemotherapy may contribute to prolonged survival in patients with advanced lung cancer.

Alvarez A, Cerda-Nicolas M, Naim Abu Nabah Y et al (2004) Direct evidence of leukocyte adhesion in arterioles by angiotensin II. Blood 104:402–408. doi:10.1182/blood-2003-08-2974 CrossRefPubMed

Anandanadesan R, Gong Q, Chipitsyna G et al (2008) Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1/2 signaling. J Gastrointest Surg 12:57–66. doi:10.1007/s11605-007-0403-9 CrossRefPubMed

Arrieta O, Guevara P, Escobar E et al (2005) Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma. Br J Cancer 92:1247–1252. doi:10.1038/sj.bjc.6602483 CrossRefPubMed

Attoub S, Gaben AM, Al-Salam S et al (2008) Captopril as a potential inhibitor of lung tumor growth and metastasis. Ann N Y Acad Sci 1138:65–72CrossRefPubMed

Christian JB, Lapane KL, Hume AL et al (2008) Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial. J Natl Cancer Inst 100:1223–1232. doi:10.1093/jnci/djn262 CrossRefPubMed

Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358:1160–1174. doi:10.1056/NEJMra0707704 CrossRefPubMed

Cohen MH, Gootenberg J, Keegan P et al (2007) FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12:713–718. doi:10.1634/theoncologist.12-6-713 CrossRefPubMed

Delbaldo C, Michiels S, Rolland E et al (2007) Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. Cochrane Database Syst Rev CD004569

Deshayes F, Nahmias C (2005) Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 16:293–299. doi:10.1016/j.tem.2005.07.009 CrossRefPubMed

Egami K, Murohara T, Shimada T et al (2003) Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 112:67–75PubMed

Friis S, Sorensen HT, Mellemkjaer L et al (2001) Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer 92:2462–2470. doi:10.1002/1097-0142(20011101)92:9<2462::AID-CNCR1596>3.0.CO;2-L CrossRefPubMed

Fujita M, Hayashi I, Yamashina S et al (2005) Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 26:271–279. doi:10.1093/carcin/bgh324 CrossRefPubMed

Greco S, Muscella A, Elia MG et al (2003) Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells. J Cell Physiol 196:370–377. doi:10.1002/jcp.10313 CrossRefPubMed

Jones PH, Christodoulos K, Dobbs N et al (2004) Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer. Br J Cancer 91:30–36. doi:10.1038/sj.bjc.6601897 CrossRefPubMed

Kjeldsen SE, Julius S (2004) Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Am Heart J 148:747–754. doi:10.1016/j.ahj.2004.04.037 CrossRefPubMed

Lever AF, Hole DJ, Gillis CR et al (1998) Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352:179–184. doi:10.1016/S0140-6736(98)03228-0 CrossRefPubMed

Li CI, Malone KE, Weiss NS et al (2003) Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65–79 years. Cancer 98:1504–1513. doi:10.1002/cncr.11663 CrossRefPubMed

McMillan DC, Elahi MM, Sattar N et al (2001) Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer 41:64–69. doi:10.1207/S15327914NC41-1&2_8 CrossRefPubMed

Miyajima A, Kosaka T, Asano T et al (2002) Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 62:4176–4179PubMed

Molina JR, Adjei AA, Jett JR (2006) Advances in chemotherapy of non-small cell lung cancer. Chest 130:1211–1219. doi:10.1378/chest.130.4.1211 CrossRefPubMed

Noguchi R, Yoshiji H, Kuriyama S et al (2003) Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. Clin Cancer Res 9:6038–6045PubMed

Prisant LM (2008) Management of hypertension in patients with cardiac disease: use of renin-angiotensin blocking agents. Am J Med 121:S8–S15. doi:10.1016/j.amjmed.2008.05.017 CrossRefPubMed

Redondo-Muller MA, Stevanovic-Walker M, Barker S et al (2008) Anti-cancer actions of a recombinant antibody (R6313/G2) against the angiotensin II AT1 receptor. Endocr Relat Cancer 15:277–288. doi:10.1677/ERC-07-0068 CrossRefPubMed

Rizkalla B, Forbes JM, Cooper ME et al (2003) Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptors. J Am Soc Nephrol 14:3061–3071. doi:10.1097/01.ASN.0000099374.58607.C9 CrossRefPubMed

Ruilope LM (2005) Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers? Acta Diabetol 42(Suppl 1):S33–S41. doi:10.1007/s00592-005-0179-x CrossRefPubMed

Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98. doi:10.1056/NEJMoa011954 CrossRefPubMed

Suzuki Y, Ruiz-Ortega M, Lorenzo O et al (2003) Inflammation and angiotensin II. Int J Biochem Cell Biol 35:881–900. doi:10.1016/S1357-2725(02)00271-6 CrossRefPubMed

Takeda H, Kondo S (2001) Differences between squamous cell carcinoma and keratoacanthoma in angiotensin type-1 receptor expression. Am J Pathol 158:1633–1637PubMed

Uemura H, Ishiguro H, Nakaigawa N et al (2003) Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther 2:1139–1147PubMed

Uemura H, Ishiguro H, Kubota Y (2006) Angiotensin II receptor blocker: possibility of antitumor agent for prostate cancer. Mini Rev Med Chem 6:835–844. doi:10.2174/138955706777698633 CrossRefPubMed

Uemura H, Ishiguro H, Kubota Y (2008) Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment. Int J Urol 15:19–26PubMed

van der Knaap R, Siemes C, Coebergh JW et al (2008) Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: the Rotterdam Study. Cancer 112:748–757. doi:10.1002/cncr.23215 CrossRefPubMed

Volpert OV, Ward WF, Lingen MW et al (1996) Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 98:671–679. doi:10.1172/JCI118838 CrossRefPubMed

Williams CJ, Woods R, Levi J et al (1988) Chemotherapy for non-small cell lung cancer: a randomized trial of cisplatin/vindesine v no chemotherapy. Semin Oncol 15:58–61PubMed

Yasumatsu R, Nakashima T, Masuda M et al (2004) Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells. J Cancer Res Clin Oncol 130:567–573. doi:10.1007/s00432-004-0582-7 CrossRefPubMed

Zambidis ET, Soon Park T, Yu W et al (2008) Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells. Blood 112:3601–3614. doi:10.1182/blood-2008-03-144766 CrossRefPubMed

Titel: Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy
verfasst von: Stefan Wilop
Sabine von Hobe
Martina Crysandt
Albert Esser
Rainhardt Osieka
Edgar Jost
Publikationsdatum: 01.10.2009
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 10/2009
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-009-0587-3

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2009

Polymorphisms of survivin promoter are associated with risk of esophageal squamous cell carcinoma

RETRACTED ARTICLE: Overexpression of Cks1 is associated with poor survival by inhibiting apoptosis in breast cancer

Expression of anion exchanger 1 is associated with tumor progress in human gastric cancer

A joint detection of CEA and CA-50 levels in saliva and serum of patients with tumors in oral region and salivary gland

Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo

High expressions of vascular endothelial growth factor and platelet-derived endothelial cell growth factor predict poor prognosis in alpha-fetoprotein-negative hepatocellular carcinoma patients after curative resection

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie